A Study of MGC026 in Participants With Advanced Solid Tumors
← catalyst calendarNCT06242470 · readout ≤ 650 d
Sponsored by MacroGenics (industry) · MGNX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
250estimated
Sites
12
Countries
Australia, United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-06 | actual | When the study began enrolling |
| Primary completion | May 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Advanced Cancer
- Metastatic Cancer
- Squamous Cell Carcinoma of Head and Neck
- Non Small Cell Lung Cancer
- Small-cell Lung Cancer
- Bladder Cancer
- Sarcoma
- Endometrial Cancer
- Melanoma
- Castration Resistant Prostatic Cancer
- Cervical Cancer
- Colorectal Cancer
- Gastric Cancer
- Gastro-esophageal Cancer
- Pancreas Cancer
- Clear Cell Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Platinum-resistant Ovarian Cancer
- Breast Cancer
- Ovarian Cancer
- Esophageal Squamous Cell Cancer (SCC)
Interventions
- Biological: MGC026 Dose Escalation
- Biological: MGC026 Dose for Expansion
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest.
measured Throughout the study, up to 135 weeks
Permalink · MGNX's whole pipeline · Catalyst calendar · Every registered study · What changed